CRISM Therapeutics Corporation
AMMCF
$6.77
$6.573,309.57%
| Weiss Ratings | AMMCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | AMMCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | AMMCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | AMMCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -- | |||
| 30-Day Total Return | -- | |||
| 60-Day Total Return | -- | |||
| 90-Day Total Return | -- | |||
| Year to Date Total Return | -- | |||
| 1-Year Total Return | -- | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -- | |||
| 52-Week Low % Change | -- | |||
| Price | AMMCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | -- | |||
| 52-Week Low Price | -- | |||
| 52-Week Low Price (Date) | -- | |||
| 52-Week High Price (Date) | -- | |||
| Valuation | AMMCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | -- | |||
| Enterprise Value | 337.31K | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.11 | |||
| Earnings Per Share Growth | -- | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -- | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | -- | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -- | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | AMMCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 8.71M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -325.98% | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AMMCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | -- | |||
| Address | -- | |||
| Website | www.crismtherapeutics.com | |||
| Country | British Virgin Islands | |||
| Year Founded | 2016 | |||
| Profitability | AMMCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 0.00% | |||
| Profit Margin | -51,313.82% | |||
| Management Effectiveness | AMMCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 0.00% | |||
| Return on Equity | 0.00% | |||
| Income Statement | AMMCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 18.80K | |||
| Total Revenue (TTM) | 18.80K | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -67.40K | |||
| EBIT (TTM) | 0.00 | |||
| Net Income (TTM) | -9.65M | |||
| Net Income Avl. to Common (TTM) | -9.65M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 320.99% | |||
| EPS Diluted (TTM) | -1.11 | |||
| EPS Diluted Growth (Q YOY) | 60.33% | |||
| Balance Sheet | AMMCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 4.38M | |||
| Cash Per Share (Q) | $0.50 | |||
| Total Current Assets (Q) | 4.79M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 4.12M | |||
| Current Ratio (Q) | 7.230 | |||
| Book Value Per Share (Q) | $0.47 | |||
| Total Assets (Q) | 4.79M | |||
| Total Current Liabilities (Q) | 662.00K | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 662.00K | |||
| Total Common Equity (Q) | 4.12M | |||
| Cash Flow | AMMCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 34.93M | |||
| Cash from Financing (TTM) | -31.45M | |||
| Net Change in Cash (TTM) | 187.00K | |||
| Levered Free Cash Flow (TTM) | 24.60M | |||
| Cash from Operations (TTM) | -2.77M | |||
